PhenoPath pathologists are nationally recognized thought leaders in many areas of pathology. The team actively publishes and they often serve as invited speakers at regional, national and international pathology workshops and professional meetings. Our pathologists are backed by technologists with years of experience in histology, IHC, flow cytometry and molecular testing. Because we are dedicated to clinical excellence, you can be assured of accurate, up-to-date and authoritative case reporting, incorporating the latest developments in the classification and analysis of tumors. We are readily accessible via email or telephone to discuss any aspect of your case.
Dr. Ussakli has had outstanding pathology training, both in her native Turkey and in the United States. She received her medical degree at Hacettepe University in Ankara, and then completed a four year Residency in Pathology. Upon coming to the United States in 2010, Dr. Ussakli was a Senior Research Scientist at the University of Washington, and in 2016 she completed her Anatomic and Clinical Pathology Residency, also at the University of Washington. Subsequently, she was awarded a GI and Hepatobiliary Pathology Fellowship, followed by a second Fellowship in Molecular and Genetic Pathology, also at the University of Washington. She has a strong academic background, as evidenced by her 28 peer-reviewed publications. Here at PhenoPath, Dr. Ussakli will be sharing responsibilities on the immunohistochemistry and FISH services, while providing valuable insights as PhenoPath brings on our next generation sequencing service in the next few months.
Publications (limited selection)
Tretiakova M, Fulton R, Kocherginsky M, Long T, Ussakli C, Antic T, Gown A.Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of 4 commonly used antibodies and RNA expression. Mod Pathol. 2017 Dec 22 [Epub ahead of print].
Ussakli C, Usubutun A, Dincer N, Dolgun A, Bülbül D, Isikdogan Z, Haberal N, Ozen O, Tezel GG.Serous versus high-grade endometrioid endometrial carcinoma: immunohistochemistry of RFP is not useful for differentiation. Pol J Pathol 2016; 67 (3): 221-227
Soylemezoglu F, Himmetoglu C, Oguz KK, Saygi S, Akalan N. A 41-Year-Old Man wıth Drug-Resistant Complex Partial Seizures. Brain pathology (Zurich, Switzerland). 2015; 25 (4): 511-2.
Kamburoğlu HO, Kayikcioglu AU, Himmetoglu Ç. A case of myoepithelioma mimicking a parotid cyst. Ear, nose, & throat journal. 2015; 94 (1): 37-9.
Risques RA, Ussakli C, Salk JJ, Rabinovitch PS, Brentnall TA. Response. Journal of the National Cancer Institute. 2014; 106 (2): djt437.
Ussakli CH, Ebaee A, Binkley J, Brentnall TA, Emond MJ, Rabinovitch PS, Risques RA.Mitochondria and tumor progression in ulcerative colitis. Journal of the National Cancer Institute. 2013; 105 (16): 1239-48.
Salk JJ, Bansal A, Lai LA, Crispin DA, Ussakli CH, Horwitz MS, Bronner MP, Brentnall TA, Loeb LA, Rabinovitch PS, Risques RA.Clonal expansions and short telomeres are associated with neoplasia in early-onset, but not late-onset, ulcerative colitis. Inflammatory bowel diseases. 2013; 19 (12): 2593-2602.
Spencer ES, Johnston RB, Gordon RR, Lucas JM, Ussakli CH, Hurtado-Coll A, Srivastava S, Nelson PS, Porter CR. Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality. The Prostate. 2013; Jan 17. doi: 10.1002/pros.2263 : Jan 17. doi: 10.1002/pros.2263.
Tezel GG, Ordulu Z, Himmetoglu C, Usubütün A.The Selective Expression of Ret Finger Protein in Endometrial Cancer: Can RFP be a Marker of Serous Carcinomas? Turk Patoloji Derg. 2012; 28 (3): 213-219.
Guler G, Balci S, Costinean S, Ussakli CH, Irkkan C, Suren D, Sari E, Altundag K, Ozisik Y, Jones S, Bacher J, Shapiro CL, Huebner K.Stem cell-related markers in primary breast cancers and associated metastatic lesions. Modern Pathology. 2012; 25 (7) : 949-955.
Onder S, Kosemehmetoglu K, Himmetoglu C, Firat P, Uner A. Sclerosing angiomatoid nodular transformation (SANT) of spleen: a case report describing cytology, histology, immunoprofile and differential diagnosis. Cytopathology. 2011; 23 (2) : 129-132.
Guler G, Himmetoglu C, Jimenez RE, Geyer SM, Wang WP, Costinean S, Pilarski RT, Morrison C, Suren D, Liu J, Chen J, Kamal J, Shapiro CL, Huebner K. Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features. Breast Cancer Res Treat. 2011; 129 (2) : 421-432.
Risques RA, Lai LA, Himmetoglu C, Abaee A, Li L, Feng Z, Bronner MP, Al-Lahham B, Kowdley KV, Lindor KD, Rabinovitch PS, Brentnall TA.Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer Research. 2010; 71 (5) : 1669-1679.
Kiratli H, Erkan K, Himmetoglu C, Uner A. Lateral rectus muscle involvement in leukemia. Clin Experiment Ophthalmol. 2010; 38 (6): 651-652.
Dincer N, Tezel GG, Sungur A, Himmetoglu C, Huebner K, Guler G. Study of FHIT and WWOX expression in mucoepidermoid carcinoma and adenoid cystic carcinoma of salivary gland. Oral Oncology. 2010; 46 (3) : 195-199.
Dr. Fulton received his MD and PhD from the University of Minnesota, and completed his postgraduate training in Anatomic Pathology at Stanford University. Following residency, he completed two fellowships (Surgical Pathology and Immunodiagnosis) at Stanford University, and is board-certified in Anatomic Pathology.
Dr. Fulton worked at Kaiser Permanente Medical Center in San Francisco, CA for 12 years and served in the roles of Chief of Pathology, Assistant Chief of the Medical Center Quality Department and Medical Director of the Kaiser Regional IHC Laboratory and Consultation Service.
In addition to his extensive experience in diagnostic immunohistochemistry, Dr. Fulton served on the College of American Pathologists IHC Committee (2009 to 2014), as well as the CAP Workgroup for IHC Validation Guidelines. He is the founder and CEO of Array Science, LLC and holds a patent for a method and apparatus for making tissue and cell culture microarrays. This company received a National Cancer Institute-Small Business Innovations Research award to further develop this technology. He also serves on the scientific advisory boards for several companies in the biotechnology field.
Dr. Fulton joined PhenoPath Laboratories, Seattle, WA in September 2013 as attending pathologist and Director of Contract Research. In addition, Dr. Fulton is actively involved in expert consultation and surgical pathology responsibilities, and the development and validation of new assays. Together with Dr. Allen Gown and Dr. Jason Hornick, Dr. Fulton serves on the faculty of a two-day course on Diagnostic Immunohistochemistry offered by the ASCP. He now serves as Secretary/Treasurer of the newly-formed International Society of Immunohistochemistry and Molecular Morphology.
Publications (limited selection)
Gown AM, Fulton RS, Kandalaft PL. Markers of metastatic carcinoma of breast origin. Histopathology, 68(1):86-95, 2016.
Garcia C, Kubat JS, Fulton RS, Anthony AT, Combs M, Powell CB, Littell RD. Clinical outcomes and prognostic markers in uterine leiomyosarcoma: a population-based cohort. Int J Gynecol Cancer, 25(4):622-8, 2015.
Fehrenbacher PL, Capra AM, Quesenberry Jr CP, Fulton R, Shiraz P, Habel LA. Distant Invasive Breast Cancer Recurrence Risk in Human Epidermal Growth Factor Receptor 2–Positive T1a and T1b Node-Negative Localized Breast Cancer Diagnosed From 2000 to 2006: A Cohort From an Integrated Health Care Delivery System. J Clin Onc, 32(20), 2151-2158, 2014.
Fitzgibbons PL1, Bradley LA, Fatheree LA, Alsabeh R, Fulton RS, Goldsmith JD, Haas TS, Karabakhtsian RG, Loykasek PA, Marolt MJ, Shen SS, Smith AT, Swanson PE. Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med, 138(11):1432-43, 2014.
Pan M, Hoodfar E., Bergoffen J, Fulton R, Hofmeister L, Chavez A, Li D. Improving Detection of Lynch Syndrome Using a Reflex Immunohistochemistry Algorithm for all Patients with Newly Diagnosed Colorectal Caner. ASCO Quality Care Symposium Presentation, San Diego, CA, 2012.
Yaziji H, Eisen R, Wick M, Badve S, Cartun R, Haas T, Marolt M, Hicks D, Martin A, Barry T, Alsabeh R, Taylor J, Fulton R, Goldsmith J, Shen S, Taylor C, Swanson P. Immunohistochemistry cocktails are here to stay: Center for Medicare and Medicaid Services should revise its new reimbursement policy. Am J Clin Pathol 138(1):10-1, 2012.
Yaziji H, Eisen R, Wick M, Swanson P, Badve S, Cartun R, Haas T, Marolt M, Hicks D, Martin A, Barry T, Alsabeh R, Taylor J, Fulton R, Goldsmith J, Shen S, Taylor C. Immunohistochemistry cocktails are here to stay: Center of Medicare and Medicaid Services should revise its new reimbursement policy. Appl Immunohistochem Mol Morphol 20(4):331-3, 2012.
Goldsmith JD, Allred DC, Beasley MB, Eisen R, Fulton RS, Gown AM, Hammond ME. Fixation time does not affect expression of HER2/neu. Am J Clin Pathol 135(3):484, author reply 485, 2011.
Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, Caan BJ. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 11(3):R31, 2009.
Mattoch IW, Fulton R, Kim Y, Hoppe R, Warnke RA, Sundram UN. Cutaneous peripheral T-cell lymphoma associated with a proliferation of B cells. Am J Clin Pathol 131(6):810-9, 2009.
Yoon M, Desai K, Fulton R, Bucci K, Russin M, Conway RM, O’Brien J. Desmoplastic small round cell tumor presenting in the orbit with associated visual symptoms. Arch Ophthalmol 123(4):565–567, 2005.
Fulton RS, Rouse RV, Ranheim EA. Ectopic prostate: case report of a presacral mass presenting with obstructive symptoms. Arch Pathol Lab Med 125(2):286-8, 2001.
Harvell JD, Fulton R, Jones CD, Terris DJ, Warnke RA. Composite dendritic cell neoplasm (NOS) and small lymphocytic lymphoma. Appl Immunohistochem Mol Morphol 8(4):322-8, 2000.
Ciaravino G, Kapp DS, Vela AM, Fulton RS, Lum BL, Teng NN, Roberts JA. Primary leiomyosarcoma of the vagina. A case report and literature review. Int J Gynecol Cancer 10(4):340-347, 2000.
In addition to Associate Medical Director, Steven J. Kussick, MD, PhD, is Director of Contract Research, and Director of Flow Cytometry at PhenoPath Laboratories. He has extensive experience in the use of morphologic, immunophenotypic, and molecular methods in the diagnosis of hematolymphoid neoplasms. Dr. Kussick received his M.D. and Ph.D. from the Medical Scientist Training Program at the University of Washington, where he also completed his Anatomic Pathology Residency and Hematopathology Fellowship. He is board-certified in Anatomic Pathology and Hematopathology. Prior to joining PhenoPath, he was Attending Hematopathologist and Associate Director of Hematopathology in the Department of Laboratory Medicine at the University of Washington. At PhenoPath, Dr. Kussick established our 9-color flow cytometry laboratory in 2005, and transitioned the methodology to 10-color analysis in 2010. He has overseen the validation of numerous new IHC assays related to hematopathology. In addition to 14 years of attending experience in diagnostic hematopathology, Dr. Kussick has a broad research background, with over 35 peer-reviewed research publications in areas including flow cytometry, hematopathology, basic cancer biology and chronic disease epidemiology.
Publications (limited selection)
Bohling S, Davis E, Thompson K, Kussick SJ, Love J. Flow cytometric analysis of CD200 expression by pulmonary small cell carcinoma. Cytometry Part B; in press, 2015.
Keeney M, Halley JG, Rhoads DD, Ansari MQ, Kussick SJ, Karlon WJ, Mehta KU, Dorfman DM, Linden MA. Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program. Arch Pathol Lab Med 139: 1276- 1280, 2015.
Chen J-H, Bai D, Dabhi V, Wood BL, Kussick SJ. Clinicopathologic features of primary colonic enteropathy-associated T cell lymphoma type II in an elderly Asian male with diarrhea. J Hematopathol 8: 37-41, 2015.
Mannelli L, Monti S, Love JE, Kussick SJ, McLuen A, Behnia F.Primary Rosai-Dorfman disease of the bone in a patient with history of breast cancer: appearance on 99mTc-MDP scintigraphy, CT, and X-ray. Clin Nucl Med 40: 247-249, 2015.
Davis BH1, Dasgupta A, Kussick S, Han JY, Estrellado A; ICSH/ICCS Working Group.Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part II - preanalytical issues. Cytometry B Clin Cytom 84:286-90, 2013.
Tse CH, Hwang HC, Goldstein LC, Kandalaft PL, Wiley JC, Kussick SJ, Gown AM.Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. J Clin Oncol: 4168-74, 2011.
Furmanczyk PS, Wolgamot GM, Kussick SJ, Sabath, DE, Olerud JE, Argenyi ZB. Diagnosis of mycosis fungoides with different algorithmic approaches. J Cutan Pathol: 2010 Jan;37(1):8-14.
Gown AM, Goldstein LC, Barry TS, Kussick SJ, Kandalaft PL, Kim PM, Tse CC. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol 21: 1271-1277, 2008.
Kussick SJ. Multiparametric flow cytometry in the diagnosis of myelodysplastic syndromes and related disorders. Lab Med 38: 305-313, 2007.
Wood BL, Arroz M, Barnett D, DiGiuseppe J, Greig B, Kussick SJ, Oldaker T, Shenkin M, Stone E. Wallace P. 2006 Bethesda International Consensus Recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: Optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom (In Press, 2007).
Fromm JR, Kussick SJ, Wood BL. Identification and purification of classical Hodgkin cells from lymph nodes by flow cytometry and flow cytometric cell sorting. Am J Clin Pathol 126: 764-780, 2006.
As Director of Molecular Pathology, Harry Hwang, MD, directs the FISH and PCR services as well as participating in the general IHC consultation service. He is board-certified in Anatomic and Clinical Pathology. Dr. Hwang attended the University of Pennsylvania School of Medicine, Philadelphia, where he earned his MD and completed his AP/CP residency training at the University of Washington Medical Center, Seattle. He also completed an IHC Fellowship at PhenoPath from 2002-03 under Dr. Gown, and served as an Adjunct Pathologist prior to his full-time appointment as Director of Molecular Pathology in 2008. Dr. Hwang’s expertise in molecular pathology stems from his research studies at the Fred Hutchinson Cancer Research Center (FHCRC), Seattle, in the areas of cancer and the cell cycle. Dr. Hwang brings to PhenoPath the combined strengths of extensive diagnostic pathology experience coupled with intensive knowledge of molecular pathology.
Publications (limited selection)
Fulton R, Turner K, Crawford S, Gown AM, Liu H, Bohling S, Natividad C, von Bueren E, Rios A, Hwang H. BRAF Mutation Cross-Contamination Is Not Identified In A Large Series Of Slides Sectioned Using A Fully Robotic Microtome (TissueTek Smartsection®). Poster presentation at the Annual Meeting of the United States and Canadian Academy of Pathology, Vancouver, B.C., Canada, March 2018.
Mignano S, Williams J, Rud A, Thompson K, Bohling SD, Gown AM, Hwang H. The immune checkpoint protein PDL2 is more frequently coexpressed with PDL1 in EBV+ carcinomas compared to EBV carcinomas in mismach repair proficient tumors. Poster presentation. United States and Canadian Academy of Pathology Meeting, Vancouver, BC, Canada, March 2018.
Malignant mesothelioma in situ. Churg A, Hwang H, Tan L, Qing G, Taher A, Tong A, Bilawich A, Dacic S. Histopathology 2018 DOI: 10.1111/his.13468. Published online January 2018.
Hwang HC, Gown AM. Evaluation of Human Epidermal Growth Factor Receptor 2 (HER2) Gene Status in Human Breast Cancer Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Specimens by Fluorescence In Situ Hybridization (FISH) Methods Mol Biol. 1406:61-70, 2016.
Hwang HC, Sheffield BS, Rodriguez S, Thompson K, Tse CH, Gown AM, Churg A. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens Am J Surg Pathol. 40(1):120-6. doi: 10.1097/PAS.0000000000000529, Jan, 2016.
Sheffield BS, Tinker AV, Shen Y, Hwang H, Li-Chang HH, Pleasance E, Ch'ng C, Lum A, Lorette J, McConnell YJ, Sun S, Jones SJ, Gown AM, Huntsman DG, Schaeffer DF, Churg A, Yip S, Laskin J, Marra MA. Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing PLoS One. 2015 Mar 23;10(3):e0119689. doi: 10.1371/journal.pone.0119689. eCollection 2015.
Sheffield BS1, Hwang HC, Lee AF, Thompson K, Rodriguez S, Tse CH, Gown AM, Churg A. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations PLoS One. Am J Surg Pathol. 39(7):977-82. doi: 10.1097/PAS.0000000000000394. July, 2015.
Churg A, Allen T, Borczuk AC, Cagle PT, Galateau-Sallé F, Hwang H, Murer B, Murty VV, Ordonez N, Tazelaar HD, Wick M.Well-differentiated papillary mesothelioma with invasive foci.Am J Surg Path 38(7):990-8, 2014.
Hwang HC, Tse C, Rodriguez S, Gown AM, Churg A.p16 FISH deletion in surface epithelial mesothelial proliferations is predictive of underlying invasive mesothelioma. Am J Surg Path 38(5):681-688, 2014.
Gown AM, Goldstein LC, Hwang HC, Tse CH. Concordance between human epidermal growth factor receptor 2 testing by reverse transcriptase polymerase chain reaction and fluorescent in situ hybridization. J Clin Oncol: 1726-7, 2012.
Tse CH, Hwang HC, Goldstein LC, Kandalaft PL, Wiley JC, Kussick SJ, Gown AM. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. J Clin Oncol: 4168-74, 2011.
Kuppers DA, Hwang HC, Jackson AL, Linsley PS, Clurman BE, Fero ML. Effect of Xpcl1 activation and p27 (Kip1) loss on gene expression in murine lymphoma PLoS One 11: 6(3): e14758, 2011
Grim JE, Gustafson MP, Hirata RK, Hagar AC, Swanger J, Welcker M, Hwang HC, Ericsson J, Russell DW, Clurman BE. Isoform- and cell cycle-dependent substrate degradation by the Fbw7 ubiquitin ligase. J Cell Biol 181: 913-920, 2008.
Garrett-Engele CM, Tasch MA, Hwang HC, Fero ML, Perlmutter RM, Clurman BE, Roberts JM. A mechanism misregulating p27 in tumors discovered in a functional genomic screen. PloS Genet 3(12): e219, 2007.
Besson A, Hwang HC, Cicero S, Donovan SL, Gurian-West M, Johnson D, Clurman BE, Dyer MA, Roberts JM. Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev 21: 1731-1746, 2007.
Collins LC, Carlo VP, Hwang HC, Barry TS, Gown AM, Schnitt SJ. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers. Am J Surg Pathol 30(8): 1002-1007, 2006.
Neiman PE, Burnside J, Elsaesser K, Hwang HC, Clurman BE, Kimmel R, Delrow J. Analysis of gene expression, copy number and palindrome formation with a Dt40 enriched cDNA microarray. Subcell Biochem 40: 245-256, 2006.
Yaziji H, Battifora H, Barry TS, Hwang HC, Bacchi CE, McIntosh MW, Kussick SJ, Gown AM. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 19: 514-523, 2006.
Gustafson MP, Welcker M, Hwang HC, Clurman BE. Zcchc8 is a glycogen synthase kinase-3 substrate that interacts with RNA-binding proteins. Biochem Biophys Res Commun 338: 1359-1367, 2005.
Hwang HC, Clurman BE. Cyclin E in normal and neoplastic cell cycles. Oncogene 24: 2776-2786, 2005.
Hwang HC, Quenneville L, Yaziji H, Gown AM. Wilm's tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. App Imm Mol Morph 12(2): 122-126, 2004.
Yaziji H, Barry TS, Goldstein LC, Hwang HC, Hing AW, Gown AM. Discrepancies between immunohistochemitry and fluorescence in situ hybridization for HER-2 testing in breast cancer: The role of a quality assurance program on a cohort of 3564 patients. JCO Supplement 22: 679, 2004. (Poster presentation at 2004 ASCO Annual Meeting, New Orleans, LA, June 2004)
Yaziji H, Goldstein LC, Barry TS, Werling RW, Hwang HC, Ellis GK, Gralow JR, Livingston RB, Gown AM. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291: 1972-1977, 2004.
Werling RW, Hwang HC, Yaziji H, Gown AM. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Am J Surg Pathol 27(1): 82-90, 2003.
Hwang HC, Martins CP, Bronkhorst Y, Randel E, Berns A, Fero M, Clurman BE. Identification of oncogenes collaborating with p27Kip1-loss by insertional mutagenesis and high-throughput insertion site analysis. Proc Natl Acad Sci 99(17): 11293-11298, 2002.
Minella AC, Swanger J, Bryant E, Welcker M, Hwang HC, Clurman BE. p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr Biol 12: 1817-1827, 2002.
Werling RW, Yaziji H, Hwang HC, Gown AM. Immunohistochemical distinction of invasive from non-invasive breast lesions: a comparative study of p63 vs. calponin and smooth muscle myosin heavy chain. (Poster presentation at United States and Canadian Academy of Pathology, Chicago, IL, February 2002)
Anwar F, Edmond M, Schmidt RA, Hwang HC, Bronner MP. Retinoblastoma expression in thyroid neoplasms. Mod Pathol 13(5): 562-569, 2000.
Director of Operations and Cytogenetics
Shawna Pyott, PhD developed PhenoPath’s clinical cytogenetic service, which launched in March of 2014. Dr. Pyott received her PhD in molecular pathology from the University of Washington, Department of Pathology and completed the Clinical Cytogenetics and Molecular Genetic Fellowship Training Program at the University of Washington Medical Center (UWMC), Department of Medicine. She is board-certified in Clinical Cytogenetics (ABMGG) and is a fellow of the American College of Medical Genetics and Genomics (FACMGG). Dr. Pyott is proficient in the technical and interpretive aspects of cytogenetics and FISH for both neoplastic and non-neoplastic disorders and often consults with the PhenoPath pathologists on difficult FISH cases.
Publications (limited selection)
Pyott SM, Tran TT, Leistritz DF, Pepin MG, Mendelsohn NJ, Temme RT, Fernandez BA, Elsayed SM, Elsobky E, Verma I, Nair S, Turner EH, Smith J, Jarvik GP, and Byers PH. WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. Am J Hum Genet: 92(4):590-97, 2013.
Byers PH, Pyott SM. Recessively inherited forms of osteogenesis imperfecta. Annu Rev Genet 46:475-97, 2012.
Schwarze U, Cundy T, Pyott SM, Christiansen HE, Hegde MR, Bank RA, Pals G, Ankala A, Conneely K, Seaver L, Yandow SM, Raney E, Babovic-Vuksanovic D, Stoler J, Ben-Neriah Z, Segel R, Lieberman S, Siderius L, Al-Aqeel A, Hannibal M, Hudgins L, McPherson E, Clemens M, Sussman MD, Steiner RD, Mahan J, Smith R, Anyane-Yeboa K, Wynn J, Chong K, Uster T, Aftimos S, Sutton VR, Davis EC, Kim LS, Weis MA, Eyre D, Byers PH. Mutations in FKBP10, which result in Bruck syndrome and recessive forms of osteogenesis imperfecta, inhibit the hydroxylation of telopeptide lysines in bone collagen. Hum Mol Genet: 22(1):1-17, 2013.
Pyott SM, Schwarze U, Christiansen HE, Pepin MG, Leistritz DF, Dineen R, Harris C, Burton BK, Angle B, Kim K, Sussman MD, Weis M, Eyre DR, Russell DW, McCarthy KJ, Steiner RD, Byers PH. Mutations in PPIB (cyclophilin B) delay type I procollagen chain association and result in perinatal lethal to moderate osteogenesis imperfecta phenotypes. Hum Mol Genet: 20(8):1595-609, 2011.
Pyott SM, Pepin MG, Schwarze U, Yang K, Smith G, Byers PH. Recurrence of perinatal lethal osteogenesis imperfecta in sibships: parsing the risk between parental mosaicism for dominant mutations and autosomal recessive inheritance. Gene Med: 13(2):125-30, 2011.
Baldridge D, Lennington J, Weis MA, Homan EP, Jiang MM, Munivez E, Keene DR, Hogue WR, Pyott S, Byers PH, Krakow D, Cohn DH, Eyre DR, Lee B, Morello R. Generalized Connective Tissue Disease in Crtap-/- Mouse. PLoS One: 5(5):e10560, 2010.
Alanay Y, Avaygan H, Camacho N, Utine GE, Boduroglu K, Aktas D, Alikasifoglu M, Tuncbilek E, Orhan D, Bakar FT, Zabel B, Superti-Furga A, Bruckner-Tuderman L, Curry CJ, Pyott S, Byers PH, Eyre DR, Baldridge D, Lee B, Merrill AE, Davis EC, Cohn DH, Akarsu N, Krakow D. Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 86(4): 551-9, 2010.
Christiansen HE, Schwarze U, Pyott SM, AlSwaid A, Al Balwi M, Alrasheed S, Pepin MG, Weis MA, Eyre DR, Byers PH. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. Am J Hum Genet: 86(3):389-98, 2010.
CRO Sr. Scientist
Dr. Galina Strizheva leads the development and execution of preclinical and clinical research projects, designs new assays and implements new methodologies. She provides scientific and technical expertise and assistance to variety of CRO projects. She also leads the assay validation process and collaborates closely with our laboratory teams.
Dr. Strizheva is an accomplished scientist with over 18 years of experience as a researcher, scientific support and project leader within the commercial, clinical and research organizations in the US and Russian Federation, with expertise in immunology, molecular and cellular biology. She received her MD in Research (Medical Biochemistry, Molecular and Cell Biology) from the Russian State Medical University and performed her graduate project at Fox Chase Cancer Center. Dr. Strizheva continued her education in the US and received her MSc in Pharmacology and Physiology from Saint Louis School of Medicine. For the past six years, Dr. Strizheva worked within CRO organizations leading cell biology and immunology projects and covering assay development and validation for safety of biologics, tumor tolerance, and immune checkpoint modulators. Prior to that, Dr. Strizheva provided consultations, coaching and troubleshooting to the customers interested in IHC, Flow Cytometry, FISH and CISH research, and diagnostic products in the role of the Support Scientist at Life Technologies Corporation (now part of the Thermo Fisher Corp.). At the beginning of her career, Dr. Strizheva briefly worked in Investigative Toxicology department at Amgen and cytogenetics clinical labs at Cardinal Glennon Children’s Hospital and at Russian Children's Clinical Hospital.
Publications (limited selection)
Strizheva G, Randhawa A, Mulligan J, O’Day. Development of an in vitro pre-clinical cellular assay to predict induction of Cytokine Storm by therapeutic antibodies. The Journal of Immunology. 188, 125.16, 2012.
Strizheva G, Carsillo T, Kruger W, Sullivan E, Ryu J, Henske P. The Spectrum of Mutations in TSC1 and TSC2 in Women with Tuberous Sclerosis and Lymphangioleiomyomatosis. Am J Respir. Crit. Care Med. vol. 163 no. 1 253-258. January, 2001.
Khare L, Strizheva G, Bailey J, Au K, Northrup H, Smith M, Smalley S, Henske E. A novel missense mutation in the GTPase activating protein homology region of TSC2 in two large families with tuberous sclerosis complex. J Med Genet. 38:347–349, 2001.